Guardian Pharmacy Services, Inc. (NYSE: GRDN) has reported its financial results for the second quarter ended June 30, 2025. The company's revenue for the quarter was $344.3 million, showing a robust 15% increase compared to the same period last year. This growth was primarily driven by low double-digit organic growth and acquisitions completed over the past 12 months. The resident count at the end of the quarter stood at over 195,000, marking a 12% year-over-year increase.
However, the net income for the quarter was reported at $8.8 million, down from $15.8 million in the prior-year period. It's important to note that the significant variance in net income was primarily due to income tax expenses and share-based compensation expenses in the recently completed quarter.
On a positive note, the adjusted EBITDA for the quarter was $25.0 million, including the impact of approximately $1.1 million of costs to operate as a public company, compared to $21.7 million in the prior year period. The diluted EPS for the quarter was $0.14, with adjusted EPS of $0.23.
The company's cash and cash equivalents totaled $18.8 million at quarter-end, with no long-term debt outstanding under its credit facility. Guardian's President and CEO, Fred Burke, attributed the strong quarterly performance to disciplined execution by local pharmacy teams, growing demand from assisted living facility partners, and meaningful revenue contributions from strategic acquisitions.
In light of the performance through the first half of 2025, Guardian Pharmacy Services has raised its full-year guidance. The updated guidance now forecasts revenue in the range of $1.39 billion to $1.41 billion, up from the previous range of $1.33 billion to $1.35 billion. Similarly, the adjusted EBITDA guidance has been raised to a range of $100.0 million to $102.0 million from the previous range of $97.0 million to $101.0 million.
Throughout the quarter, Guardian expanded its national presence with the addition of two new pharmacies in Wichita, KS and Seattle, WA, as well as launching a new greenfield pharmacy in Naples, FL. Additionally, the company announced its acquisition of Managed Healthcare Pharmacy, establishing its first physical footprint in Oregon with locations in Eugene and Medford.
In May 2025, Guardian completed a non-dilutive secondary offering of 8.625 million shares of its Class A common stock, significantly increasing its public float, enhancing trading liquidity, and expanding its institutional investor base.
Following these announcements, the company's shares moved -0.45%, and are now trading at a price of $19.88. For more information, read the company's full 8-K submission here.
